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CONCLUSIONS: GA was found to reduce relapses and clinical progression com-
pared with placebo, and clinical progression in comparison with interferons. Seri-
ous adverse events were comparable with interferons. Qualitative and quantitative
methods demonstrated that the benefits of GA outweigh the risks but the results
differ substantially depending on the quantitative risk-benefit model used.
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OBJECTIVES: Cervical dystonia is a disabling, painful condition involving involun-
tary movement and posturing of the head and neck. Botulinum toxin injections are
the standard of care in the symptomatic management of this condition, but need to
be re-administered regularly to maintain a stable improvement. The duration of
clinical effect and thus, frequency of need for reinjection may be dependent on the
product used and can impact annualized drug and health care utilization costs.
METHODS: A literature search was undertaken to identify prospective or retro-
spective studies reporting duration of effect of onabotulinumtoxinA (BOTOX®). A
formal meta-analysis was conducted using Comprehensive Meta-Analysis Version
2. Both a fixed effects and random effects model were performed. The quality of
each identified journal article was evaluated using the Cho & Bero Quality scoring
instrument by two separate investigators. Differences in scores were resolved
through conference. Subgroup analyses were performed on several moderating
variables including study quality and dose of onabotulinumtoxinA. RESULTS: Of
the identified potential journal articles, 13 studies met the inclusion criteria and
were used for the meta-analysis. The duration of effect of onabotulinumtoxinA in
cervical dystonia was found to be 13.7 weeks (95% CI 13.4 – 13.9 weeks) for the fixed
effects model and 13.5 weeks (95% CI 12.7 – 14.3 weeks) for the random effects
model. A meta-regression found that the higher the quality score, the shorter the
duration of effect. Another meta-regression found that doses of onabotulinum-
toxinA greater than 200U generally resulted in a longer duration of effect than
doses below 200U. CONCLUSIONS: Based on the published literature, the duration
of effect of onabotulinumtoxinA was 13-14 weeks. This suggests that, in general,
patients with cervical dystonia treated with onabotulinumtoxinA should require
approximately 4 treatments per year. A dose-effect for duration was also identified.
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OBJECTIVES: To assess the relative efficacy and safety of high (HD) and low dose
(LD) beta interferons (IFN-1a and FN-1b) and glatiramer treatments in relapsing-
remitting multiple sclerosis. METHODS: Systematic review of literature. A bibliog-
raphy search was carried out to identify primary studies on MEDLINE and EMBASE
until February 2011. Other databases consulted were: Cochrane library, Centre for
Reviews and Dissemination, ECRI, ISI Web of Knowledge e INHATA. Inclusion cri-
teria: 1) head to head randomized clinical trials; 2) patients with relapsing-remit-
ting multiple sclerosis; and 3) Outcomes: relapse rate, proportion of relapse-free
patients, time to first relapse, expanded disability status scale, magnetic resonance
imaging outcomes and adverse effects. A quality assessment was carried out to
estimate the internal validity of the selected studies and the quality of their evi-
dence. Indirect comparison were analysed when head to head studies weren’t
available. RESULTS: Eight studies were included in this report, 5 head to head
studies between HD and LD IFN and 3 studies which compared the HD beta inter-
ferons with glatiramer. No studies were found which compared LD beta interferon
and glatiramer. The included studies had moderate internal validity. Direct com-
parison between the three beta interferons LD 1-a, HD1-a and HD1-b showed that
all of them were effective and HD IFN were better than LD IFN. There was weak
indirect and direct evidence for similar efficacy between the HD IFN. The compar-
ison HD interferons and glatiramer did not show significant differences in their
relapse rate and MRI measures. CONCLUSIONS: 1) HD interferons showed greater
efficacy at short term in reducing relapses than low-dose interferon. Currently, the
estimation of the relative efficacy of two high-dose interferons is not possible but
there is weak evidence in favor of similar efficacy, and 2) HD interferons and glati-
ramer showed similar efficacy for relapse measures at 2 years.
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OBJECTIVES: To assess the rate and clinical outcomes of using antiepileptic drugs
(AEDs) at doses above the recommended range (DARR) in pediatric outpatients
with structural-metabolic epilepsy. METHODS: Patients were followed-up retro-
spectively for one year since the first visit. Inclusion criteria were age 2 years; a
diagnosis of structural-metabolic epilepsy; AEDs treatment; and three or more
visits during the first year from the referral time. Exclusion criteria were epilepsy
surgery within the first year from the referral time; and patients not satisfied in-
clusion criteria. During the period from January to June 2010, the required data
were extracted from medical records. Assessment of AEDs doses was based on the
recommended drug doses that were mentioned in “Pediatric Protocols for Malay-
sian Hospitals”. RESULTS: Of 120 followed-up patients, only 13 (10.83%) of them
exposed to AEDs at DARR. In term of visits, 32 (5.68%) visits out of 563 demonstrated
DARR. There was no association between the uses of AEDs at DARR with age,
gender, race, child development, and seizure type. However, the uses of AEDs at
DARR were significantly higher in polytherapy than monotherapy visits (Chi-
square, p0.001). Visits included DARR led to higher seizure frequency than visits
without DARR (Mann-Whitney, P0.001). Ultimately, only patients who weren’t
exposed to AEDs at DARR showed a significant improvement in their seizure con-
trol at the last follow-up visit compared with the baseline (Wilcoxon, P0.001).
CONCLUSIONS: The low frequency of DARR indicates the knowledgeability and
awareness of the in charged pediatric neurologist about consequences of exceed-
ing average effective doses. In term of better seizure control, uses of AEDs at DARR
shows no benefit over using these agents at recommended doses.
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OBJECTIVES: Patients with RRMS can benefit from disease modifying treatments
(DMT) through delayed disease progression and reductions in relapse frequency.
For patients who continue to experience disease activity despite DMT, therapeutic
options have been limited. Understanding the relative prognosis of these sub-
optimally treated (SOT) patients is of considerable interest given the availability of
new treatment options. The aim of our study was to evaluate disease progression of
SOT and non-SOT patients enrolled to the placebo arm of the FREEDOMS® trial.
METHODS: SOT patients were identified as patients who experienced either an
unchanged relapse rate, or at least one relapse with additional disease activity
observed on MRI, despite treatment with a DMT in the prior year. For each patient
group (SOT and non-SOT), Markov state transition matrices were derived. Each
matrix evaluated the annual probability of patients transitioning between stages of
the Expanded Disability Status Scale (EDSS). Comparisons between patient groups
included time to disability greater or equal to () EDSS 4 and EDSS 6, time from
EDSS 4 to disability EDSS 6 and mean EDSS score over time. RESULTS: Median
time to EDSS 4 and EDSS 6 was 5.5 [4.5, 7.5] and 9.0 [7.0, 12.0] years in SOT
patients, compared with 10 [8.5, 12.0] and 18.5 [16.0, 22.5] years in non-SOT pa-
tients. Median time from EDSS 4 to disability greater than EDSS 6 was 3.4 [1.8, 5.4]
years in SOT compared to 5.3 [3.5, 8.0] years in non-SOT patients. Mean EDSS scores
at 2, 5 and 10 years post-onset were estimated at 1.05, 2.55 and 3.21 for SOT and
0.95, 2.13 and 3.07 for non-SOT, respectively.CONCLUSIONS:The analysis suggests
that RRMS patients who experience relapse and MRI activity despite previous treat-
ment with a DMT face faster progression to severe disability states. The analysis
highlights the importance of effective treatment options for these patients.
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OBJECTIVES:Vertigo is a crippling and stressful symptom. It involves the illusion of
movement that manifests itself with an impression of spinning. It is often accom-
panied by neurovegetative signs, but the patient remains conscious during the
attack. Vertigo, often recurrent and sometimes persistent, can strongly alter the
quality of life of patients, to the point of preventing the performance of the majority
of daily activities. It increases the risk of falling and depression or anxiety. Describe
the initial care of patients with vertigo by general practitioners in France.
METHODS: A total of 1400 general practitioners drawn by lot from the general
practitioners practicing in France were contacted, then questioned. RESULTS: The
prevalence of consultations for vertigo and, this being any type of vertigo, is 5.57%,
with one in three is being recurrent vertigo, with an incidence of 2.49%. 45% of the
vertigo cases were not associated with an underlying known pathology (for exam-
ple, a middle ear infection or brain tumour), 40 % of the benign paroxysmal posi-
tional vertigos, 9% Ménière’s disease, 6% a vestibular neuronitis or neuritis 69% of
cases of recurrent vertigo not associated with an underlying pathology are treated
by oral an anti-vertigo drugs, 4% are intravenous, 27% benefit from 2 galenic. Fifty-
seven percent of the general practitioners directly treat their patients’ vertigo, the
others refer them to a specialist. CONCLUSIONS: The epidemiology of recurrent
vertigo (upon the first appearance) has not been studied. It is necessary to point out
that vertigo is, for the most part, recurrent. The interest in this work responds to
this problem situation.
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OBJECTIVES: We used the World Health Organisation database (Vigibase) to eval-
uate the contribution of a global spontaneous adverse event (AE) database for an
analysis of benefit-risk for Glatiramer acetate (GA) in multiple sclerosis.METHODS:
Vigibase is a passive surveillance system that in 2011 contained over 6 million
reports of spontaneous AEs suspected of being linked to health care products from
regulatory authorities in nearly 90 countries. GA, interferon beta-1a, interferon
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beta-1b (interferons) and natalizumab and the reactions suspected of being asso-
ciated with them were identified. Disproportionality analyses used the Multi-item
Poisson Gamma Shrinker method with WHO-ART diagnosis at the preferred term
level for all AEs and for the standard combination of all WHO =critical terms=.
Statistical significance for disproportionality was defined as an Empirical Bayesian
Geometric Mean lower fifth percentile (EBGM05) 2.0. Comparisons were made
between GA versus all other drugs and GA versus interferons and natalizumab.
Sales data for GA were available to calculate reporting rates. RESULTS: A total of
2,320 cases with 6,680 AEs with a suspected relationship with GA and 20,155 cases
with 72,326 AEs for interferons and natalizumab were identified. Compared with all
other drugs in Vigibase and with interferons and natalizumab, GA was associated
with several statistically significant observations of disproportionate reporting.
WHO =critical terms= combined were not higher for GA versus interferons and
natalizumab (EBGM of 0.84 (90% credibility interval 0.79-0.90). The reporting rate of
WHO =critical terms= for GA was 69 events/100,000 person-year. CONCLUSIONS: In
a risk-benefit analysis of GA based on traditional meta-analysis, the number of AEs
in eligible controlled placebo/untreated and head-to-head studies were limited. In
such a situation analysis of a global large spontaneous AEs database permitted the
assessment of non-common and important risks. However, the biases inherent in
these databases need to be addressed.
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OBJECTIVES:Ambulation is the most highly valued bodily function for MS patients
(Heesen et al.), with ambulation problems recorded in up to 75% of patients (Hobart
et al.). Fampridine is a first-in-class treatment for ambulation. It improves the
conductivity of the nerves where demyelination has occurred. A preliminary bud-
get impact model (BIM) has been created to analyse the impact of introducing
fampridine to treat MS patients with walking impairment in the UK market.
METHODS: The BIM calculates the budget impact from a UK payer perspective of
introducing fampridine in addition to usual care to an eligible MS patient popula-
tion suffering from ambulation problems with an Expended Disability Severity
Scale (EDSS) between 4 and 7.5, using a 3 year time horizon and a market forecast.
The model conservatively assumes that all patients respond to treatment and
there is no effect of fampridine on usual care resource use. A monthly withdrawal
rate is also applied. RESULTS: The acquisition cost of fampridine is estimated at
£3800 per patient per year. An approximate eligible population of 35,000 MS pa-
tients is estimated from literature. The market forecast estimates an uptake of 3%,
10% and 16% of the eligible population in the first three years respectively, and the
estimated withdrawal rate is 2.2%. Compared to usual care alone, the annual re-
sults for the first three years show an additional budget of £3.4million, £10.9million
and £18.2million respectively. CONCLUSIONS: The model presents conservative
estimates whilst still showing a relatively low impact on the payer’s budget, dem-
onstrating that a major unmet need of MS patients can be met without a large
increase in budget. Further research is required into response rates, effect of fam-
pridine on usual care treatment costs to get a more accurate estimate of the impact
fampridine.
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OBJECTIVES: To assess the budget impact of the treatment for Relapsing Remitting
Multiple Sclerosis (RRMS), interferons, and glatiramer acetate, from the National
Health System (NHS) perspective.METHODS:A budget impact model was designed
to compare the cost of RRMS treatment in different settings, using a 5 year time-
horizon, considering different percentages of administration of each medication. A
reference setting o base case using all the available first line treatments (interfer-
ons and glatiramer acetate) was compared with 5 alternatives scenarios excluding
each one of these treatments. The cost analysis (2010 euros) includes direct med-
ical resources (drugs, administration, visits, disease management, diagnostic
tests). Unitary cost data was obtained from the health costs database e-Salud and
drugs Catalogue. RESULTS: Considering a cohort of 22,255 patients with RRMS, the
mean global budget impact per year would be € 260.775.470 in the base case. The
setting that excluded glatiramer acetate increases the budget impact in a 3.23% (€
372 per patient per year). Pharmacological costs were the key drivers of total cost
(90%). CONCLUSIONS: The use of glatiramer acetate in the first-line-treatment of
RRMS patients is a cost-saving strategy, which may decrease the budget impact
from the NHS perspective in Spain.
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OBJECTIVES: To estimate costs of managing corticosteroid (CS)-related adverse
events (AEs) within a systemic lupus erythematosus (SLE) population.METHODS:A
retrospective claims analysis (January 1, 2000–June 30, 2010) was conducted within
an SLE population to evaluate the risk of known CS-related chronic and acute AEs
among CS users and non-users by utilizing Cox proportional hazards models ad-
justing for patient characteristics, SLE severity, other SLE treatments, and AE-re-
lated risk factors. Associated costs were computed for AEs where the risk was
significantly different among CS users compared to non-users. CS users having a
chronic AE were followed for 12 months post-AE date to capture total costs, which
were compared to total costs of CS users who did not have a chronic AE during the
same time period. Predicted annual costs were generated using generalized linear
models controlling for baseline characteristics. The incremental difference in an-
nual costs among the two groups was considered attributable to the AE. For pa-
tients having an acute AE, disease-specific costs were calculated over a 12-month
timeframe post-AE date. RESULTS: SLE patients receiving CS were more likely to
develop chronic AEs (ie, cataracts, sleep disturbances, hypertension, type II diabe-
tes, migraine) and acute AEs (ie, pneumonia, herpes zoster, fungal infections, nau-
sea/vomiting). The average annual cost for managing AEs was highest for type II
diabetes ($9763), followed by hypertension ($8774), sleep disturbances ($5599), mi-
graine ($3591), cataracts ($2407), herpes zoster ($2079), pneumonia ($1726), nausea/
vomiting ($1357), and fungal infections ($857). When applying base rates and in-
creased risk estimates of each AE to the cost estimates, it costs an additional
$784/year per CS user to manage known CS-related AEs compared to CS non-users.
CONCLUSIONS: Within an SLE population, CS treatment is associated with addi-
tional costs of $784/year due to management of CS-related AEs. Providers and
payers should consider these potential costs of CS when making treatment deci-
sions.
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OBJECTIVES: Approximately 50% of patients do not achieve seizure control with a
single antiepileptic drug (AED). With the advent of multiple AEDs in the past 15
years, the choice of optimal polytherapy remains difficult in absence of clinical
studies about the effectiveness of various combination therapies. This study aimed
at describing the current management of focal epilepsy treated by polytherapy in
France and at estimating the extra-costs of pharmacoresistance (PR) as redefined in
2009 by the International League Against Epilepsy (ILAE). METHODS: ESPERA is a
European multicenter, observational, cross-sectional study conducted in France
and Spain in 2010. A random sample of neurologists enrolled prospectively a sam-
ple of adult patients treated with at least two antiepileptic drugs (AEDs) in combi-
nation for focal epilepsy. The investigators classified their patients according to the
new ILAE criteria and this classification was then reviewed by two independent
experts. All items of medical resources use associated with epilepsy were collected
retrospectively over the last year and valued according to a societal perspective.
RESULTS: Seventy-one French neurologists collected analysable data on 405 pa-
tients. After review by experts, patients were finally classified as PR in 286 (70.6%) of
them, in 91 (22.4%) as responsive and in 28 (7%) as undefined. The mean annual
epilepsy related direct costs par patient were 4238 € (SD: 3772) in PR patients as
compared with 1907€ (SD: 1,739) in responsive patients. AEDs costs were estimated
2602€ and 1544€ respectively and PR patients were significantly more often hospi-
talized (mean annual cost: 1023€ versus 78€) and had more procedures (mean an-
nual cost: 194€ versus 53€). CONCLUSIONS: Despite the number of therapeutic
alternatives available in epileptic patients, a large proportion of them remain with
uncontrolled seizures yielding to significant extra costs.
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OBJECTIVES: To compare the expected costs (EC) of three different screening strat-
egies for cystic fibrosis implemented in Spain: TIR/DNA/DGGE, TIR/TIR/DNA, and
TIR/DNA. These strategies correspond to screening programs in Basque Country,
Castilla León and Canary Islands. METHODS: For each strategy, EC per child
screened, also EC per infant with CF and EC disaggregated by type of test was
estimated. In addition, sensitivity of each strategy was calculated. Unless there are
differences between unit cost along communities, the same unit cost source for all
programs was used, in order to allow comparisons. RESULTS: The estimated EC per
screened neonate were € 3.67, € 4.07, € 4.11 for TIR/ADN, TIR/ADN/DGGE, and TIR/
TIR/ADN respectively, showing that TIR/ADN/DGGE is the strategy with lowest EC
for its population. Regarding the sensitivity of the three strategies, the results
showed similar and high values for all of them, being the strategy of Basque Coun-
try which had highest value (99.37%). The ECs per neonate suffering CF were
82.703,48 €, 18.726,29 €, 16.604,10 € for TIR/ADN, TIR/ADN/DGGE, and TIR/TIR/ADN
respectively, showing highest cost per neonate with the disease, however the
power of this results is still low, and there are differences between incidences along
strategies. CONCLUSIONS: In this cost comparative study it was obtained that the
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